Published in Cancer Cell on June 01, 2004
Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol (2005) 3.44
Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell (2008) 2.35
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med (2008) 2.10
The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci U S A (2005) 1.89
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res (2006) 1.69
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res (2008) 1.66
Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res (2005) 1.39
Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol (2005) 1.38
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 1.37
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res (2006) 1.35
An intramolecular folding sensor for imaging estrogen receptor-ligand interactions. Proc Natl Acad Sci U S A (2006) 1.35
Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res (2010) 1.34
Ligand-specific dynamics of the androgen receptor at its response element in living cells. Mol Cell Biol (2006) 1.28
Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol (2007) 1.25
Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal (2012) 1.23
Imaging molecular interactions in living cells. Mol Endocrinol (2005) 1.23
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations. Clin Cancer Res (2012) 1.22
PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J (2007) 1.19
Rapid signaling by steroid receptors. Am J Physiol Regul Integr Comp Physiol (2008) 1.18
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res (2007) 1.15
The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res (2005) 1.14
A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling. J Biol Chem (2010) 1.09
Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway. Mol Cancer Res (2008) 1.07
CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP. Genes Dev (2010) 1.05
Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation. Proc Natl Acad Sci U S A (2013) 1.05
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat (2009) 1.05
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? Nat Rev Clin Oncol (2012) 1.04
Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat (2008) 1.03
A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer (2011) 1.02
Derailed estrogen signaling and breast cancer: an authentic couple. Endocr Rev (2012) 1.01
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer (2006) 1.00
A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples. BMC Genomics (2013) 1.00
Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PLoS One (2009) 0.99
Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun (2013) 0.99
The role of S6K1 in ER-positive breast cancer. Cell Cycle (2012) 0.98
Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene (2010) 0.95
Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol (2009) 0.94
Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells. PLoS One (2008) 0.93
Visualizing the action of steroid hormone receptors in living cells. Nucl Recept Signal (2007) 0.93
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol (2009) 0.92
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Mol Cancer Ther (2008) 0.92
Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer. Proc Natl Acad Sci U S A (2014) 0.91
Application of phosphorylation site-specific antibodies to measure nuclear receptor signaling: characterization of novel phosphoantibodies for estrogen receptor alpha. Nucl Recept Signal (2006) 0.90
δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer. PLoS One (2012) 0.89
Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. Endocrinology (2009) 0.89
Survey of phosphorylation near drug binding sites in the Protein Data Bank (PDB) and their effects. Proteins (2014) 0.88
Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat (2014) 0.87
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A (2015) 0.84
p21-activated kinase signaling in breast cancer. Breast Cancer Res (2004) 0.83
Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer. Oncogene (2013) 0.83
Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305. Mol Cancer Res (2012) 0.83
p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget (2015) 0.82
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem (2010) 0.81
Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer (2015) 0.79
Synergistic Activation of ERα by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1. Cancer Res (2016) 0.79
Intercalation of XR5944 with the estrogen response element is modulated by the tri-nucleotide spacer sequence between half-sites. J Steroid Biochem Mol Biol (2011) 0.79
PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype. Med Mol Morphol (2012) 0.79
Ubiquitylation of nuclear receptors: new linkages and therapeutic implications. J Mol Endocrinol (2015) 0.79
Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer (2012) 0.78
The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention. Acta Biochim Biophys Sin (Shanghai) (2015) 0.77
LSD1 engages a corepressor complex for the activation of the estrogen receptor α by estrogen and cAMP. Nucleic Acids Res (2016) 0.76
The Estrogen Receptor α-Cistrome Beyond Breast Cancer. Mol Endocrinol (2016) 0.76
Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells. Mol Cell (2017) 0.76
DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944. Curr Top Med Chem (2015) 0.75
Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha. J Mol Model (2014) 0.75
Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell (2006) 11.01
A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Cross-presentation by intercellular peptide transfer through gap junctions. Nature (2005) 3.03
Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol (2003) 3.00
Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep (2004) 2.98
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65
A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J Cell Biol (2006) 2.55
Correcting confocal acquisition to optimize imaging of fluorescence resonance energy transfer by sensitized emission. Biophys J (2004) 2.55
Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54
A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity (2004) 2.53
Rab proteins, connecting transport and vesicle fusion. Traffic (2005) 2.52
Activation of endosomal dynein motors by stepwise assembly of Rab7-RILP-p150Glued, ORP1L, and the receptor betalll spectrin. J Cell Biol (2007) 2.52
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol (2008) 2.49
Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. J Cell Biol (2009) 2.45
Bright cyan fluorescent protein variants identified by fluorescence lifetime screening. Nat Methods (2010) 2.43
Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol (2005) 2.27
A comparison of donor-acceptor pairs for genetically encoded FRET sensors: application to the Epac cAMP sensor as an example. PLoS One (2008) 2.23
DNA damage triggers nucleotide excision repair-dependent monoubiquitylation of histone H2A. Genes Dev (2006) 2.22
TRPM7, a novel regulator of actomyosin contractility and cell adhesion. EMBO J (2006) 2.20
Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature (2007) 2.19
Integrins control motile strategy through a Rho-cofilin pathway. J Cell Biol (2005) 2.04
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) 1.96
Calcium signaling regulates translocation and activation of Rac. J Biol Chem (2003) 1.94
Agonist-induced PIP(2) hydrolysis inhibits cortical actin dynamics: regulation at a global but not at a micrometer scale. Mol Biol Cell (2002) 1.93
Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science (2013) 1.91
Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. Immunity (2003) 1.89
Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell (2007) 1.89
Late endosomal transport and tethering are coupled processes controlled by RILP and the cholesterol sensor ORP1L. J Cell Sci (2013) 1.79
Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood (2013) 1.74
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2005) 1.73
Gold-enhanced biomolecular surface imaging of cells and tissue by SIMS and MALDI mass spectrometry. Anal Chem (2006) 1.71
Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape. Immunity (2005) 1.64
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast (2009) 1.62
Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res (2006) 1.59
PIP2 signaling in lipid domains: a critical re-evaluation. EMBO J (2005) 1.59
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56
Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53
A mTurquoise-based cAMP sensor for both FLIM and ratiometric read-out has improved dynamic range. PLoS One (2011) 1.49
Glucosylated hydroxymethyluracil, DNA base J, prevents transcriptional readthrough in Leishmania. Cell (2012) 1.46
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Rab7 and Rab27a control two motor protein activities involved in melanosomal transport. Pigment Cell Res (2006) 1.39
RhoB regulates endosome transport by promoting actin assembly on endosomal membranes through Dia1. J Cell Sci (2005) 1.39
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
MHC class II molecules on the move for successful antigen presentation. EMBO J (2007) 1.38
Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. Proc Natl Acad Sci U S A (2005) 1.36
Translocation of PKC[theta] in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C. J Cell Biol (2002) 1.35
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation. EMBO J (2011) 1.34
On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc (2013) 1.32
8-pCPT-2'-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue. Chembiochem (2008) 1.32
A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. Genome Res (2004) 1.32
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol (2002) 1.31
Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J Immunol (2006) 1.27
TRPM7 is required for breast tumor cell metastasis. Cancer Res (2012) 1.27
Regulation of connexin43 gap junctional communication by phosphatidylinositol 4,5-bisphosphate. J Cell Biol (2007) 1.25
Dynein-mediated vesicle transport controls intracellular Salmonella replication. Mol Biol Cell (2004) 1.24
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2010) 1.24
Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J Am Soc Nephrol (2009) 1.24
Recombination-induced tag exchange to track old and new proteins. Proc Natl Acad Sci U S A (2009) 1.23
Activation of TRPM7 channels by phospholipase C-coupled receptor agonists. J Biol Chem (2006) 1.21
Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A (2003) 1.20
PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO J (2007) 1.19
WAPL-mediated removal of cohesin protects against segregation errors and aneuploidy. Curr Biol (2013) 1.19
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
Direct spatial control of Epac1 by cyclic AMP. Mol Cell Biol (2009) 1.17
A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol (2007) 1.15
A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell (2011) 1.14
Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat Res (2004) 1.14